Corbus Pharmaceuticals is mounting a David vs. Goliath battle against Seagen, spending $7.5 million of its dwindling cash reserves on a challenger to the nectin-4 antibody-drug conjugate (ADC) Padcev.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results